PTC Therapeutics PTCT unveils its next round of earnings this Thursday, July 29. Get prepared with Benzinga's ultimate preview for PTC Therapeutics's Q2 earnings.
Net Income, Earnings, And Earnings Per Share
Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.
Earnings And Revenue
PTC Therapeutics's per-share loss will be near $1.82 on sales of $110.50 million, according to Wall Street analysts. PTC Therapeutics EPS in the same period a year ago totaled $2.62. Sales were $75.24 million.
Why Analyst Estimates And Earnings Surprises Are Important
Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.
The Wall Street estimate would represent a 30.53% increase in the company's earnings. Revenue would be up 46.87% from the year-ago period. PTC Therapeutics's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|
| EPS Estimate | -1.51 | -0.94 | -0.04 | -1.30 |
| EPS Actual | -1.83 | -1.08 | -1.03 | -2.62 |
| Revenue Estimate | 98.80 M | 111.36 M | 111.88 M | 82.78 M |
| Revenue Actual | 117.94 M | 118.86 M | 118.40 M | 75.24 M |
Want Real-Time Earnings Calendar Updates?
Benzinga consistently updates its earnings calendars to stay up-to-date with the latest company earnings reports. Check out the full earnings calendar list updated in real-time by following this link.
Stock Performance
Shares of PTC Therapeutics were trading at $39.03 as of July 27. Over the last 52-week period, shares are down 17.42%. Given that these returns are generally negative, long-term shareholders are probably upset going into this earnings release.
Do not be surprised to see the stock move on comments made during its conference call. PTC Therapeutics is scheduled to hold the call at 16:30:00 ET and can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
